{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.147","value":"0.21"},{"groupId":"OG001","spread":"3.711","value":"1.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Overall (All Randomized Participants)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.246","value":"-1.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"FLC Subtype Kappa"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.744","value":"0.69"},{"groupId":"OG001","spread":"3.711","value":"1.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"FLC Subtype Lambda"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Change in heart function was measured by GLS%, a noninvasive imaging technique that uses echocardiography to assess heart. GLS% expresses longitudinal shortening as a percentage (change in length as a proportion to baseline length) and is reported as a negative value. A more negative value is usually associated with cardiac enhancement.","dispersionType":"Standard Deviation","groups":[{"description":"During the PETP, participants were administered CAEL-101 as an IV infusion over approximately 2 hours, in addition to SoC plasma cell dyscrasia treatment. All participants continued their double-blind treatment until LPI+18 months.\n\nAll participants had the option to enter into the OLEP, where they continued to receive CAEL-101 in addition to any SoC prescribed by a physician.","id":"OG000","title":"CAEL-101 + Plasma Cell Dyscrasia Treatment"},{"description":"During the PETP, participants were administered placebo as an IV infusion over approximately 2 hours, in addition to SoC plasma cell dyscrasia treatment. All participants continued their double-blind treatment until LPI+18 months.\n\nAll participants had the option to enter into the OLEP, where they continued to receive CAEL-101 in addition to any SoC prescribed by a physician.","id":"OG001","title":"Placebo + Plasma Cell Dyscrasia Treatment"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat Set: all participants who were randomized. As prespecified, data collected and reported as 'Overall (All Randomized Participants)' and per subgroups 'Kappa FLC Subtype' and 'Lambda FLC Subtype'. Here, 'Overall Number of Participants Analyzed' and 'Number Analyzed' signifies those participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 50","title":"Change From Baseline in Global Longitudinal Strain (GLS%)","type":"SECONDARY","unitOfMeasure":"percentage of myocardial shortening"}